Year: 2025
Type: article
Abstract: ROS1 rearrangements represent a rare but clinically significant oncogenic driver in non-small cell lung carcinoma (NSCLC), occurring in approximately 1–2% of cases. While crizotinib and entrectinib are established targeted therapies, limitations such as central nervous system (CNS) progression and acquired resistance underscore the need for next-generation inhibitors. Taletrectinib, a highly selective ROS1 tyrosine kinase inhibitor, has shown promising activity in both TKI-naïve and pretreated patients, including those with CNS metastases and resistance mutations like G2032R. Early-phase clinical trials report encouraging objective response rates with a manageable safety profile, distinguishing taletrectinib as a potential best-in-class therapy. Its favorable pharmacokinetics and brain penetration may address key gaps left by earlier ROS1 inhibitors, particularly for patients with intracranial disease progression. Given the unmet clinical need, taletrectinib represents an important advancement in precision oncology for ROS1-positive NSCLC. Ongoing phase II and III studies will be crucial in validating its efficacy and positioning within treatment algorithms. Integration of taletrectinib into clinical practice has the potential to improve survival outcomes and quality of life in this molecularly defined subset of NSCLC patients.
Source: INNOVAPATH
DOI: 10.63501/z87b0k37
Authors: EESHA SAEED, Muhammad Salman, Syeda Aleena Ilyas, Syed Usman Ali Shah, Ghulam Rasti, Sawera Ramzan
Institution: Ayub Medical College
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4414320775